Home > Boards > US Listed > Medical - Drugs > Revive Therapeutics Ltd. (RVVTF)

Pennsy,

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
RioDad Member Profile
 
Followed By 17
Posts 889
Boards Moderated 0
Alias Born 08/24/20
160x600 placeholder
Revive Therapeutics Enters Into Research Agreement with UCSF For Bucillamine As Potential Treatment For Severe COVID-19 InvestorsHub NewsWire - 5/3/2021 9:32:33 AM
Revive inks research agreement to explore use of Bucillamine in treating severe COVID-19 Seeking Alpha - 5/3/2021 9:27:48 AM
Revive Therapeutics Files For FDA Orphan Drug Designation for Psilocybin in Traumatic Brain Injury InvestorsHub NewsWire - 4/27/2021 9:51:20 AM
Revive files for FDA orphan drug status for psilocybin in traumatic brain injury Seeking Alpha - 4/27/2021 9:33:08 AM
Revive Therapeutics Announces Successful Research Results for Oral Thin Film Psilocybin and Filing of U.S. Provisional ....cont InvestorsHub NewsWire - 4/22/2021 8:26:06 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 InvestorsHub NewsWire - 3/24/2021 9:15:00 AM
Revive Therapeutics provides update on late-stage Bucillamine study in COVID-19 Seeking Alpha - 3/24/2021 9:08:15 AM
Revive Therapeutics Announces Successful Research Results for Psilocybin to Treat Traumatic Brain Injury and Filing of ...Cont InvestorsHub NewsWire - 3/19/2021 7:56:39 AM
Revive Therapeutics posts positive data from pre-clinical psilocybin brain injury study Seeking Alpha - 3/19/2021 7:37:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion...Cont InvestorsHub NewsWire - 2/26/2021 9:01:27 AM
Revive Therapeutics Acquires Unique Psilocybin Assets InvestorsHub NewsWire - 2/17/2021 9:53:14 AM
Revive Therapeutics acquires psilocybin assets for C$10M Seeking Alpha - 2/17/2021 9:38:20 AM
Revive Therapeutics Provides Update on Cannabinoid Pharmaceuticals Program InvestorsHub NewsWire - 2/11/2021 8:05:24 AM
Revive Therapeutics in Phase 3 clinical trial for COVID-19 treatment InvestorsHub NewsWire - 1/27/2021 8:13:52 AM
How Combat Sports Are Researching Micro-Dosing Psychedelics To Treat Brain Injuries InvestorsHub NewsWire - 1/18/2021 9:51:54 AM
Revive Therapeutics Announces Research Collaboration with North Carolina State University InvestorsHub NewsWire - 1/14/2021 8:30:27 AM
Dr. John Fahy Joins Revive Therapeutics as Scientific and Clinical Advisor for COVID-19 FDA Phase 3 Study InvestorsHub NewsWire - 12/31/2020 8:30:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine InvestorsHub NewsWire - 12/23/2020 9:57:14 AM
Revive Therapeutics Announces LOI to Acquire PharmaTher's Psilocybin Program InvestorsHub NewsWire - 12/22/2020 11:05:23 AM
Biotech Report; Upcoming FDA Reviews and Promising Pipelines InvestorsHub NewsWire - 12/22/2020 8:20:00 AM
Epidemiologist Dr. Joel Moody Joins Revive Therapeutics as Medical and Clinical Advisor InvestorsHub NewsWire - 12/3/2020 8:30:00 AM
Revive Therapeutics Provides Update on Oral Thin Film Product with Psilocybin InvestorsHub NewsWire - 11/12/2020 9:00:00 AM
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 InvestorsHub NewsWire - 10/30/2020 1:39:31 PM
Revive Therapeutics Signs Supply Agreement With Havn Life Sciences for Psychedelic Compounds InvestorsHub NewsWire - 10/20/2020 10:58:17 AM
RioDad   Monday, 02/01/21 12:31:40 AM
Re: Pennsy post# 23469
Post # of 26358 
Pennsy,

I will correct you.
I hink some of those here have confused you.

MF never stated he would share data news at end of year.
That is over enthusiastic iHub boarders who are projecting their wishes upon other’s expectations.
He did state that they would hit initial data point by end of 2020.

In fact if you look at what MF says, he has been vague.
Why?
> they’re small, they have to play by the rules
> they are in constant contact with FDA,
> they’re protecting their patent application

But, you have to look beyond what Revive says.

He did acknowledge that 210 mark was enrolled by years end.
He just got more funding.
He hired a Thiol Donor Researcher.
Pharm-Olam has expanded sites.

The 1000 patient trial mark should be hit by February 1st, so I imagine data would come prior to the end of February. But we’ll see, because like everyone on here, it’s a best guess.

In fact right now, Only Pharm-Olam personnel probably know any results.



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist
Consent Preferences